The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Differentiation between the EGFR antibodies necitumumab (Neci), cetuximab (Cetux), and panitumumab (Pan): Glycosylation and IgE reactivity.
D. Yu
Employment or Leadership Position - ImClone Systems
J. Wuertz
No relevant relationships to disclose
A. Taqui
No relevant relationships to disclose
Z. Li
Employment or Leadership Position - ImClone Systems
F. E. Fox
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
J. Qian
Employment or Leadership Position - ImClone Systems
T. Liu
Employment or Leadership Position - ImClone Systems
Stock Ownership - ImClone Systems
M. Li
Employment or Leadership Position - ImClone Systems
M. Hsieh
Employment or Leadership Position - ImClone Systems
Q. Zhou
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly